-
Beyond statins: LDL diversity PCSK9 pipeline Selected products targeting proprotein convertase subtilisin/kexin 9 (PCSK9) to treat hypercholesterolemia. Source: BCIQ: BioCentury Online Intelligence Company Product…
Published on 4/30/2012
-
Most next-generation lipid-lowering drugs are being developed as add-ons to high-dose statins in patients who have not hit LDL goals. New data suggest different mechanisms may be appropriate for different populations.
Published on 4/30/2012
-
While antibody inhibitors of PCSK9 have begun to report proof-of-concept data, other ways to inhibiting the target include small molecules and RNAi-based approaches.
Published on 4/30/2012
-
Prompted by Eric Topol, J&J has found a potential new application for its CellSearch technology -- predicting heart attacks.
Published on 4/16/2012
-
Rather than beating down LDL-C with a sledgehammer, Esperion's lipid modulator beneficially affects a host of metabolic risk factors including LDL-C, inflammation, blood pressure and glucose.
Published on 4/16/2012
-
GlaxoSmithKline will use Angiochem's peptide technology to develop enzyme replacements that target the CNS as well as the periphery, giving them the potential to replace current drugs.
Published on 3/12/2012
-
FDA has been quietly test-driving informatics platforms to complement and augment existing safety surveillance techniques. MolecularHealth's MASE software system is the most recent.
Published on 3/5/2012
-
Novartis' deal with Enanta gives the pharma two angles for targeting HCV that act directly and indirectly against the non-structural protein 5A, providing a one-two punch against resistance.
Published on 3/5/2012
-
The lessons from Vertex's Kalydeco for cystic fibrosis can be broadly applied to other efforts where venture philanthropy, aggressive drug development, and efficient regulatory oversight could accelerate the creation of…
Published on 3/5/2012
-
The hedgehog pathway drives specific cancers in different ways, which could explain why FDA approved Genentech's vismodegib for basal cell carcinoma while Infinity's saridegib failed in pancreatic cancer.
Published on 3/5/2012
-
Until it is known how Karo Bio's eprotirome caused cartilage damage in a 12-month dog study, other companies working on thyroid hormone receptor beta agonists may find partnering difficult.
Published on 2/27/2012
-
Threshold's decision to switch its focus to hypoxia-activated prodrugs is paying off. In the span of two weeks, the biotech has partnered with Merck KGaA and reported positive Phase IIb data in pancreatic cancer.
Published on 2/27/2012
-
How Intellikine built its PI3K platform.
Published on 2/27/2012
-
Take your PI(3)K PI3K deal flow At least nine deals primarily focusing on compounds that inhibit phosphoinositide 3-kinase (PI3K) and/or its isoforms were completed over the past seven years for more than $3 billion…
Published on 2/27/2012
-
Take your PI(3)K PI3K pipeline At least 11 compounds in the clinic have been designed to be isoform-selective inhibitors of phosphoinositide 3-kinase (PI3K), although most appear to inhibit two or three isoforms …
Published on 2/27/2012
-
Questions remain about the optimal selectivity profiles for PI3K inhibitors, but big biopharmas have already snapped up most of the next-generation inhibitors through M&A and licensing.
Published on 2/27/2012
-
Gilead's data for GS-7977 plus ribavirin in HCV genotype 1 null responders perhaps should not have been surprising; the next shoe to drop will be data for treatment-naïve patients in March.
Published on 2/20/2012
-
Armed with its first clinical efficacy data, OncoGenex expects its OGX-427, a first-in-class inhibitor of Hsp27, will play a key role in preventing resistance to cancer therapies.
Published on 2/20/2012
-
Resetting expectations ELECTRON arms The Phase Ilb ELECTRON trial was originally expected to enroll only treatment-naïve genotype 2 or 3 patients, but has been expanded twice to include a monotherapy arm, treatment-…
Published on 2/20/2012
-
Chimerix has its first POC data for CMX001, a broad-spectrum cidofovir-lipid conjugate designed to treat and prevent CMV and other dsDNA viral infections in transplant patients.
Published on 2/13/2012
-
Thrombolytic Science thinks its TS01 will be able to specifically target stroke-causing clots, significantly reducing bleeding side effects and widening the treatment window compared with tPA.
Published on 2/6/2012
-
MorphoSys started from scratch to build Ylanthia, a new antibody library that the company will launch this year to replace its aging HuCAL platform.
Published on 1/30/2012
-
A Phase III trial of Biocon's anti-CD6 mAb itolizumab showed lower efficacy than other biologics in psoriasis, but the biotech hopes lower infection rates will differentiate it from the anti-TNFs.
Published on 1/23/2012
-
Servier is optioning an anti-B7-H3 mAb from MacroGenics to add a multi-pronged mechanism that could be an improvement on immunomodulatory mAbs that target other B7 family proteins, such as Yervoy from BMS.
Published on 1/2/2012
-
Doctors say the latest Phase III data for pertuzumab support use in first-line metastatic breast cancer, but they are more excited about upcoming data in early stage disease.
Published on 12/19/2011